

LIMITED REVIEW REPORT

*To the Board of Directors
Anglo-French Drugs & Industries Limited,
41, 3rd Cross, V Block, Rajajinagar,
Bangalore - 560 010.*

We have Reviewed the accompanying statement of Unaudited financial results of Anglo-French Drugs & Industries Limited for the quarter ended 31st December 2015 except for the disclosures regarding 'Public Shareholding' and Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors their meeting held on 1st February 2016. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner, in which it is to be disclosed, or that it contains any material misstatement.

Place: Bangalore
Date: 01.02.2016



For RAY & RAY
Chartered Accountants

Mrinal Kanti Bandyopadhyay
MRINAL KANTI BANDYOPADHYAY
Partner

Membership No. 051472
Firm Registration No.301072E

h

Un Audited Financial Results for the quarter and Nine months ended 31st December 2015 (Standalone)

SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED

PARTICULARS	(in ₹ Lacs except equity share and per equity share data)					(in ₹ Lacs)	
	Quarter ended 31st December 2015	Quarter ended 30th September 2015	Nine months ended 31st December 2015 (Apr-Dec 15)	Nine months ended 31st December 2014 (Apr-Dec 14)	9 months ended 31st March 2015 (Audited) July-Mar 15	Quarter ended 31st December 2014	9 months ended 31st March 2015 (Audited) July-Mar 15
1. Income from Operations	2780	3050	8448	8192	8070		
(a) Net Sales / Income from Operations (Net of Excise Duty)	35	61	153	71	92		
(b) Other Operating Income	2816	3141	8601	8363	8162		
Total Income from operations (Net) (a+b)							
2. Expenses							
a. Changes in Inventories of Finished goods, work in progress & Stock in Trade	28	(94)	(49)	(134)	15		
b. Cost of Material Consumed	888	996	2580	2807	2619		
c. Purchase of Stock in Trade	500	600	1634	1486	1578		
d. Employee Benefit Expenses	500	565	1547	1382	1382		
e. Depreciation and Amortisation Expenses	40	42	124	128	136		
f. Other expenditure	803	888	2465	2362	2221		
Total Expenses	2759	2995	8300	8041	7951		
3. Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)	57	146	301	222	211		
4. Other Income	55	4	68	122	72		
5. Profit from Ordinary activities before Finance Costs and Exceptional Items	112	150	369	344	283		
6. Finance Costs	78	73	225	215	207		
7. Profit from Ordinary activities after Finance Costs but before Exceptional Items (5-6)	34	77	144	129	76		
8. Exceptional Items	0	0	0	0	0		
9. Profit/(+)/Loss(-) from Ordinary Activities before Tax (7+8)	34	77	144	129	76		
10. Tax Expenses	0	0	0	0	0		
- Current	0	0	0	0	0		
- Deferred	0	0	0	0	0		
11. Net Profit/(+)/Loss(-) from Ordinary Activities after Tax (9-10)	34	77	144	129	76		
12. Extraordinary Item (net of tax expense)	0	0	0	0	0		
13. Net Profit/(+)/Loss(-) for the period	34	77	144	129	76		
14. Paid up equity share capital (Face Value: 10/- each)	116	116	116	116	116		
15. Reserves excluding revaluation reserve	1669	1654	1669	1663	1825		
16. Earning per share (in ₹)							
a) Basic and Diluted before Extraordinary Item	2.92	6.64	12.36	11.10	4.98		
b) Basic and Diluted after Extraordinary Item	2.92	6.64	12.36	11.10	4.98		
17. Public Shareholding							
- No. of shares (Face value of: 10/- each)	457455	458055	457455	547855	547855		
- Percentage of shareholding	39.33	39.40	39.35	47.13	47.15		
18. Promoters and Promoter Group Shareholding							
a) Fledged/Encumbered	0	0	0	0	0		
- Number of Shares	0	0	0	0	0		
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0	0	0	0	0		
b) Non-encumbered	0	0	0	0	0		
- Number of Shares	0	0	0	0	0		
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0	0	0	0	0		
- Percentage of shares (as a % of the total shareholding of the Company)	0	0	0	0	0		



Handwritten signature

PARTICULARS	(in ₹ Lacs)				
	Quarter ended 31st December 2015	Quarter ended 30th September 2015	Quarter ended 31st December 2015 (Apr-Dec 15)	Nine months ended 31st December 2014 (Apr-Dec 14)	9 months ended 31st March 2015 (Audited) July-Mar 15
1. Segment Revenue					
a. Pharma	2847	3138	8650	8347	8200
b. Furnishing	23	7	58	38	24
c. Subsidiary	0	0	0	0	0
d. Unallocated	0	0	0	0	0
Total	2871	3145	8669	8385	8224
Less: Inter Segment Revenue	0	0	0	0	0
Total Income	2871	3145	8669	8385	8224
2. Segment Results (Profit (+)/Loss(-) before tax and interest from each segment)					
a. Pharma	101	159	371	366	324
b. Furnishing	17	(4)	(6)	(2)	(28)
c. Subsidiary	0	0	0	0	0
d. Unallocated	0	0	0	(3)	0
Total	118	155	381	355	296
Less:					
i) Interest (net)	(78)	(73)	(66)	(215)	(207)
ii) Other Unallocable expenditure net of unallocable income	(5)	(6)	(7)	(9)	(13)
Total Profit/(Loss) before tax after extraordinary item	34	77	144	129	76
3. Capital Employed (Segment Assets - Segment Liabilities)					
a. Pharma	1763	1596	1457	1457	1487
b. Furnishing	150	181	191	191	183
c. Subsidiary	0	0	0	0	0
d. Unallocated	9	(27)	(40)	(40)	(29)
Total	1923	1750	1608	1608	1641

Summary of Assets & Liabilities as at 31st December 2015		for the Nine months ended 31.12.2015	
PARTICULARS	Nine months ended 31st December 2015	9 months ended 31st March 2015 (Audited)	July 14 - Mar 15
A. EQUITY AND LIABILITIES			
1. Shareholder's Funds			
(a) Share Capital	116	116	
(b) Reserves and Surplus	1,669	1,525	
(c) Money received against share warrants			
2. Non-Current Liabilities			
(a) Long-term borrowings	693	657	
(b) Deferred tax liabilities (Net)	119	119	
(c) Other Long term liabilities	322	308	
(d) Long term provisions	43	43	
3. Current Liabilities			
(a) Short-term borrowings	1,605	1,483	
(b) Trade payables	2,162	1,708	
(c) Other current liabilities	933	752	
(d) Short-term provisions	213	213	
TOTAL EQUITY AND LIABILITIES	7,876	6,925	
B. ASSETS			
1. Non-current assets			
(a) Fixed assets			
(i) Tangible assets	1,421	1,415	
(ii) Intangible assets			
(iii) Capital work-in-progress			
(iv) Intangible assets under development	45	45	
(b) Non-current investments			
(c) Deferred tax assets (net)			
(d) Long term loans and advances	256	213	
(e) Other non-current assets			
2. Current assets			
(a) Current investments	1,960	1,944	
(b) Inventories	2,963	2,359	
(c) Trade receivables			
(d) Cash and cash equivalents	46	52	
(e) Short-term loans and advances	1,110	838	
(f) Other current assets	35	79	
TOTAL ASSETS	7,876	6,925	

Particulars	for the Nine months ended 31.12.2015
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	3
Disposed of during the quarter	3
Remaining unresolved at the end of the quarter	Nil

Notes:
1. The above financial results were taken on record by the Board of Directors in their Meeting held on 1st February 2016
2. The figures in respect of previous period have been regrouped/recast wherever necessary.
3. Deferred Tax Liability amounting to Rs. 3.35 Lacs arising out of difference between Written Down Value as per Companies Act 2013 and as per Income Tax Act 1961 not considered above.

For RAY & RAY
Chartered Accountants
F.R. No. 301072E

Place: Mumbai
Date: 1st February 2016

Mrinal Kant Bandhyopadhyay
(Mrinal Kanti Bandhyopadhyay)
Partner

M. No. 051472

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

Atul Kanoria
(ATUL KANORIA)
CHAIRMAN & MANAGING DIRECTOR